# Phase 4 & Phase 5 Final Validation & Audit Report

**Status**: Verified & Certified  
**Date**: September 18, 2026  
**Auditor**: ML Engineering & Data Integrity System  
**Master Plan Reference**: `COMORBIDITY_ENSEMBLE_ML_PLAN.md` (Sections 2, 4, 6, 8)  

---

## 1. Executive Summary & Verification Certification

A comprehensive programmatic and statistical audit was conducted across all Phase 4 (**Feature Engineering & Target Dissection EDA**) and Phase 5 (**Train / Validation / Test Splitting**) components, datasets, and pipelines. 

All 5 core integrity pillars passed all checks with zero errors, zero temporal leakage, zero patient overlap across splits, and 100% automated test pass rate (26/26 unit tests).

**Certification Statement:**
> **`PHASE 4–5 VERIFIED — READY FOR PHASE 6`**

---

## 2. Comprehensive Pillar-by-Pillar Verification

### Pillar 1: Feature Correctness & Temporal Non-Leakage
- **Observation Boundary Constraint**: All 89 ML feature predictors are strictly computed as-of index encounter end date $T$ (`condition_start_date <= landmark_date`).
- **Zero Temporal Leakage Verified**: Verified against raw `condition_occurrence.parquet` that no patient diagnosed with a condition after $T$ receives an active `has_hist_<cid>` flag at $T$ (0 leakage rows detected).
- **Network Interface Isolation**:
  - All 8 network feature columns (`net_max_relative_risk`, `net_mean_relative_risk`, `net_n_significant_edges`, `net_shortest_path_length`, `net_personalized_pagerank`, `net_target_degree_centrality`, `net_target_community_overlap`, `network_features_available`) are strictly fixed-schema placeholders.
  - Contract defaults verified: `network_features_available = 0.0`, `net_shortest_path_length = -1.0`, risk and centrality scores $= 0.0$.
  - Zero graph-derived data is present in Phase 4 feature matrices.
- **Completeness**: Zero NULL values across all numerical, binary, demographic, and burden features.

### Pillar 2: Target Correctness & Label Integrity
- **Target Space Stability**: Exactly $K = 41$ curated chronic comorbidity target columns (`target_<cid>`) are preserved across all prediction and split tables.
- **Pre-Existing Disease Masking**: Verified that no patient with an existing diagnosis at or before $T$ is assigned a positive incident label (`target_<cid> == 0` for all pre-existing rows; 0 false incidents detected).
- **Strict Label Binary Domain**: Verified 100% of values in all 41 target columns are strictly binary $\{0, 1\}$.
- **Window Alignment**: Incident diagnoses strictly fall in $(T, T + 365\text{ days}]$.

### Pillar 3: Split Correctness & Strict Patient Isolation
- **Strict Patient-Level Partitioning**: Every patient (`person_id`) is assigned to exactly **one** split across their entire longitudinal history.
  - Inter-split patient overlap: **`0` patients** (100% disjoint).
- **Prospective Temporal Holdout (`test`)**:
  - Cutoff Date: `2016-01-01`.
  - 100% of Test landmarks occur on or after `2016-01-01` (Calendar range: `2016-01-01` to `2019-05-17`).
- **Historical Train & Validation Splits (`train` & `val`)**:
  - 100% of Train and Validation landmarks occur strictly prior to `2016-01-01` (Calendar range: `1910-02-08` to `2015-12-31`).
  - Partitioned via deterministic hashing (`hash(person_id || '_split_seed_42')`) into ~70% Train and ~30% Validation.
- **Boundary-Crossing Patient Handling**:
  - Patients spanning across `2016-01-01` are assigned to their majority side.
  - Minority-side rows (43,433 in Cohort A) are dropped to prevent cross-boundary temporal or snapshot leakage.
- **Determinism**: 100% bit-for-bit identical split assignments on repeated executions.

### Pillar 4: Dataset Integrity & Row Accounting
| Metric | Cohort A (Inpatient & ED) | Cohort B (General Encounters) |
|---|---|---|
| **Raw Eligible Landmarks (Phase 3)** | 325,259 | 3,364,928 |
| **Total Unique Patients** | 80,467 | 115,223 |
| **Feature Matrix Dimensions** | 325,259 rows $\times$ 96 cols | 3,364,928 rows $\times$ 96 cols |
| **Retained Split Landmarks (Phase 5)** | 281,826 | 2,595,951 |
| **Dropped Boundary-Crossing Rows** | 43,433 | 768,977 |
| **Duplicate `landmark_id` Rows** | **0** | **0** |
| **Join Multiplication Anomalies** | **0** | **0** |
| **Missing / NULL Target Values** | **0** | **0** |

---

## 3. Exact Split Sizes (Cohort A - Inpatient & ED)

| Split | Patient Count | Patient % | Landmark Rows | Landmark % | Min Landmark Date | Max Landmark Date | Mean Age |
|---|---|---|---|---|---|---|---|
| **Train** | 44,661 | 55.5% | 174,660 | 62.0% | `1910-02-08` | `2015-12-31` | 44.5 yrs |
| **Validation** | 19,106 | 23.7% | 73,862 | 26.2% | `1910-04-23` | `2015-12-31` | 44.5 yrs |
| **Test (Temporal)** | 16,700 | 20.8% | 33,304 | 11.8% | `2016-01-01` | `2019-05-17` | 47.9 yrs |
| **Total Retained** | **80,467** | **100.0%** | **281,826** | **100.0%** | `1910-02-08` | `2019-05-17` | 44.9 yrs |

---

## 4. Final ML Feature Set Specification for Phase 6

Total Columns in Feature Parquet: **96 columns**
- **Excluded Metadata / Index Columns (7 columns)**:
  `person_id`, `landmark_id`, `visit_occurrence_id`, `visit_concept_id`, `is_inpatient_or_ed`, `landmark_date`, `future_observation_complete`
- **Excluded Network Placeholder Columns (8 columns)**:
  `net_max_relative_risk`, `net_mean_relative_risk`, `net_n_significant_edges`, `net_shortest_path_length`, `net_personalized_pagerank`, `net_target_degree_centrality`, `net_target_community_overlap`, `network_features_available`

### Active ML Feature Predictor Vector $X$ (Exact 81 Columns):
1. **Demographic Features (16 columns)**:
   - Continuous: `age_at_landmark`
   - Decade one-hot bins (7): `age_lt_30`, `age_30_39`, `age_40_49`, `age_50_59`, `age_60_69`, `age_70_79`, `age_gte_80`
   - Sex (2): `gender_male`, `gender_female`
   - Race (4): `race_white`, `race_black`, `race_asian`, `race_other`
   - Ethnicity (2): `ethnicity_hispanic`, `ethnicity_non_hispanic`
2. **Longitudinal Burden & Utilization (2 columns)**:
   - `total_prior_condition_count`, `prior_obs_years`
3. **Pre-Landmark Target Disease Diagnoses (41 columns)**:
   - `has_hist_75036`, `has_hist_79740`, `has_hist_80502`, `has_hist_192279`, `has_hist_200970`, `has_hist_201826`, `has_hist_257012`, `has_hist_258780`, `has_hist_316866`, `has_hist_317576`, `has_hist_321042`, `has_hist_378419`, `has_hist_380378`, `has_hist_381316`, `has_hist_432867`, `has_hist_436096`, `has_hist_436940`, `has_hist_439777`, `has_hist_440086`, `has_hist_443614`, `has_hist_4029498`, `has_hist_4043241`, `has_hist_4051466`, `has_hist_4079749`, `has_hist_4079750`, `has_hist_4110591`, `has_hist_4115276`, `has_hist_4120314`, `has_hist_4129902`, `has_hist_4180790`, `has_hist_4214376`, `has_hist_4226121`, `has_hist_4229440`, `has_hist_4283893`, `has_hist_4285898`, `has_hist_4310703`, `has_hist_4311629`, `has_hist_37016354`, `has_hist_37017023`, `has_hist_37395648`, `has_hist_43530652`
4. **Background Comorbidity Indicators (17 columns)**:
   - `bg_normal_bmi`, `bg_viral_sinusitis`, `bg_acute_bronchitis`, `bg_strep_or_pregnancy`, `bg_normal_pregnancy`, `bg_miscarriage`, `bg_otitis_media`, `bg_viral_pharyngitis`, `bg_appendicitis`, `bg_cystitis_uti`, `bg_gout`, `bg_alcohol_dependence`, `bg_opioid_use`, `bg_atopic_dermatitis_eczema`, `bg_suspected_condition`, `bg_suspected_respiratory_finding`, `bg_postoperative_state`
5. **Clinical Multi-Disease Interaction Terms (5 columns)**:
   - `interaction_diabetes_and_hypertension`, `interaction_hypertension_and_lipid`, `interaction_metabolic_triad`, `interaction_cvd_and_ckd`, `interaction_copd_and_cvd`

---

## 5. Automated Test Suite Verification

Ran command: `python -m pytest -v`  
**Test Results**: **26 / 26 PASSED** (100% pass rate)

```text
tests/test_features.py::test_feature_matrix_row_alignment PASSED         [  3%]
tests/test_features.py::test_feature_value_ranges_and_nulls PASSED       [  7%]
tests/test_features.py::test_feature_temporal_non_leakage PASSED         [ 11%]
tests/test_features.py::test_interaction_term_logic PASSED               [ 15%]
tests/test_features.py::test_network_interface_contract PASSED           [ 19%]
tests/test_landmarks.py::test_landmark_integrity_and_uniqueness PASSED   [ 23%]
tests/test_landmarks.py::test_temporal_observation_bounds PASSED         [ 26%]
tests/test_landmarks.py::test_censoring_flag_accuracy PASSED             [ 30%]
tests/test_landmarks.py::test_existing_disease_masking_rule PASSED       [ 34%]
tests/test_landmarks.py::test_incident_disease_positive_label_rule PASSED [ 38%]
tests/test_landmarks.py::test_outside_window_diagnoses_not_labeled PASSED [ 42%]
tests/test_landmarks.py::test_target_dataset_reproducibility PASSED      [ 46%]
tests/test_splits.py::test_zero_patient_overlap_across_splits PASSED     [ 50%]
tests/test_splits.py::test_temporal_boundary_monotonicity PASSED         [ 53%]
tests/test_splits.py::test_split_determinism_and_reproducibility PASSED  [ 57%]
tests/test_splits.py::test_split_proportions_and_non_empty PASSED        [ 61%]
tests/test_splits.py::test_target_label_integrity_in_splits PASSED       [ 65%]
tests/test_timeline.py::test_patient_integrity PASSED                    [ 69%]
tests/test_timeline.py::test_chronological_ordering PASSED               [ 73%]
tests/test_timeline.py::test_no_cross_patient_joins PASSED               [ 76%]
tests/test_timeline.py::test_date_validity PASSED                        [ 80%]
tests/test_timeline.py::test_pipeline_reproducibility PASSED             [ 84%]
tests/test_timeline.py::test_source_consistency PASSED                   [ 88%]
tests/test_timeline.py::test_demographics_count_consistency PASSED       [ 92%]
tests/test_timeline.py::test_no_join_multiplication_in_landmarks PASSED  [ 96%]
tests/test_timeline.py::test_temporal_non_leakage_and_label_masking PASSED [100%]
============================= 26 passed in 48.87s =============================
```

---

## 6. Readiness for Phase 6

All Phase 1–5 data artifacts, feature tables, labels, splits, and validation suites are complete, fully tested, and committed to version control. The project is fully unblocked and verified to begin **Phase 6: Baseline Models & Evaluation Metric Harness**.
